Cyano Biotech (acquired by Simrise Biologics)
Simris Biologics develops next-generation ADC payloads and provides high-quality cyanobacterial toxin standards and reagents.
About
Simris Biologics (previously Cyano Biotech, now a subsidiary of Simris Group) harnesses deep cyanobacterial expertise and the world’s largest cyanobacterial strain library to develop innovative, next-generation antibody-drug conjugate (ADC) payloads for cancer therapeutics. The company also manufactures high-purity cyanobacterial toxin standards and reagents, trusted by water authorities and researchers worldwide. Its proprietary technology platform enables the development of safer ADC payloads with high therapeutic indices by producing a wide array of toxin variants and bioactive natural compounds. Simris Biologics actively engages in collaborations with academic and industry partners for therapeutic, agricultural, and cosmetic applications.
Products & Services
- Next-generation ADC (Antibody-Drug Conjugate) payloads based on cyanobacterial toxins
- Cyanobacterial toxin analytical standards for HPLC and environmental analysis
- Cyanobacterial reagents (secondary metabolites such as Aeruginoguanidine 98A, Aeruginosin 98A/98B, Anabaenopeptin compounds, Microginin FR1/FR2, Oscillamide Y, etc.)
- Development of senotherapeutics for ageing-related diseases (CyAge project)
Use Cases & Case Studies
- ADC payload development for targeted cancer therapy
- Use of cyanobacterial standards for environmental toxin analysis in water samples
- Development of senotherapeutics for elimination of senescent cells in ageing-related diseases
Partnerships & Collaborations
- Berlin University of Applied Sciences (HTW) for CyAge project
- Open to collaborations with academic institutions, CDMOs, and biopharma companies
Awards & Recognition
-
Contact Information
Certifications & Compliance
- Compliance with method validation and regulatory protocols
- Certificates of Analysis (C of A) included with each product